U.S. Clinical Trial Supply and Logistics Market Size to Hit USD 3.13 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Clinical Trial Supply and Logistics Market

5.1. COVID-19 Landscape: Clinical Trial Supply and Logistics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Clinical Trial Supply and Logistics Market, By Service

8.1. U.S. Clinical Trial Supply and Logistics Market, by Service

8.1.1. Logistics & Distribution

8.1.1.1. Market Revenue and Forecast

8.1.2. Storage & Retention

8.1.2.1. Market Revenue and Forecast

8.1.3. Packaging, Labeling, and Blinding

8.1.3.1. Market Revenue and Forecast

8.1.4. Manufacturing

8.1.4.1. Market Revenue and Forecast

8.1.5. Comparator Sourcing

8.1.5.1. Market Revenue and Forecast

8.1.6. Others

8.1.6.1. Market Revenue and Forecast

Chapter 9. U.S. Clinical Trial Supply and Logistics Market, By Phase

9.1. U.S. Clinical Trial Supply and Logistics Market, by Phase

9.1.1. Phase I

9.1.1.1. Market Revenue and Forecast

9.1.2. Phase II

9.1.2.1. Market Revenue and Forecast

9.1.3. Phase III

9.1.3.1. Market Revenue and Forecast

9.1.4. Phase IV

9.1.4.1. Market Revenue and Forecast

Chapter 10. U.S. Clinical Trial Supply and Logistics Market, By End-user

10.1. U.S. Clinical Trial Supply and Logistics Market, by End-user

10.1.1. Pharmaceuticals

10.1.1.1. Market Revenue and Forecast

10.1.2. Biologicals

10.1.2.1. Market Revenue and Forecast

10.1.3. Medical Device

10.1.3.1. Market Revenue and Forecast

Chapter 11. U.S. Clinical Trial Supply and Logistics Market, By Therapeutic Area

11.1. U.S. Clinical Trial Supply and Logistics Market, by Therapeutic Area

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast

11.1.2. Cardiovascular Diseases

11.1.2.1. Market Revenue and Forecast

11.1.3. Respiratory Diseases

11.1.3.1. Market Revenue and Forecast

11.1.4. CNS and Mental Disorders

11.1.4.1. Market Revenue and Forecast

11.1.5. Others

11.1.5.1. Market Revenue and Forecast

Chapter 12. U.S. Clinical Trial Supply and Logistics Market, Regional Estimates and Trend Forecast

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Service

12.1.5.2. Market Revenue and Forecast, by Phase

12.1.5.3. Market Revenue and Forecast, by End-user

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area

Chapter 13. Company Profiles

13.1. Almac Group

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. DHL

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Parexel

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Thermo Fisher Scientific (Patheon)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Marken

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Piramal Pharma Solutions

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. UDG Healthcare

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Catalent, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FedEx

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Movianto

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The U.S. clinical trial supply and logistics market size is expected to increase from USD 1.54 billion in 2025 to USD 3.13 billion by 2035.

Answer : The U.S. clinical trial supply and logistics market is expected to grow at a compound annual growth rate (CAGR) of around 7.35% from 2026 to 2035.

Answer : The major players in the U.S. clinical trial supply and logistics market include Marken, World Courier, Fisher Clinical Services, Catalent Clinical Supply Services, Almac Group, Parexel International Corporation, Marken, PCI Pharma Service, PRA Healthsciences, and Myonex, Inc.

Answer : The driving factors of the U.S. clinical trial supply and logistics market are the rising number of complex clinical trials, increasing demand for biologics and personalized medicine, and growing need for temperature-controlled and time-sensitive drug distribution across decentralized trial sites.